1. Introduction {#sec1}
===============

Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer death worldwide \[[@B1]\]. Unlike the situation for stage II and stage III GC, there is no global agreement on adjuvant chemotherapy (AC) for stage I GC due to (1) the prognosis of stage I GC is relatively good, with over 90% of 5-year overall survival \[[@B2]\], (2) although the benefit of AC was established for patients with stage II and stage III GC, clinical trials included stage I population failed to show the benefit of AC over surgery alone \[[@B2]--[@B7]\]. However, relapse occurs in a small but definite number of patients, even those with stage I GC, after curative resection \[[@B8]\]. Moreover, recent studies showed that the prognosis and response to chemotherapy is different according to the molecular characteristics of gastric cancer \[[@B9]--[@B11]\]. Therefore, it is necessary to identify patients with stage I GC who might receive a therapeutic benefit from AC.

The role of the immune system in cancer has become increasingly prominent \[[@B12]--[@B17]\]. In addition to local inflammatory symptoms, cancer patients frequently present with systemic inflammation responses, including increased peripheral blood cell amounts and decreased serum albumin levels \[[@B18]\]. More recently, a study at the Memorial Sloan Kettering Cancer Center suggested that pretreatment neutrophil lymphocyte ratio (NLR) can be used to identify nonmetastatic melanoma patients who are more likely to benefit from adjuvant treatment \[[@B19]\]. In 2012, Proctor et al. \[[@B20]\] implemented a simplified index that is easier to apply to clinical data named the derived neutrophil-lymphocyte ratio (dNLR), and they were also able to demonstrate that the preoperative dNLR had similar prognostic value as the classical NLR. Preoperative serum albumin levels are also reported as prognostic indicators for the prognosis of cancer patients \[[@B21], [@B22]\]. These markers are inexpensive to test and routinely performed in clinical setting and hence potentially provide readily available and objective information to help clinicians to estimate patient outcome.

To the best of our knowledge, the potential influence of the pretreatment dNLR and hypoalbuminemia has never been explored in large cohorts of stage I GC patient yet. The aim of the present study was to verify the hypothesis that the systemic immune score (SIS) based on preoperative dNLR and serum albumin is associated with worse survival in diagnosed stage I GC and more importantly to investigate whether SIS can distinguish subgroups of patients who would benefit from AC. If so, such commonly measured SIS could be used in developing a strategy for selecting stage I GC treatments.

2. Materials and Methods {#sec2}
========================

2.1. Patients {#sec2.1}
-------------

A total of 1069 patients undergoing R0 resection for stage I GC at Fujian Medical University Union Hospital (FMUUH) from December 2006 to December 2016 were identified from a prospectively maintained database. The following exclusion criteria were then applied: (1) prior gastrectomy, (2) receiving neoadjuvant chemotherapy, (3) noncurative (R1/2) resection, (4) the presence of synchronous malignant disease, (5) autoimmune disorders and recent steroid therapy, and (6) incomplete medical records. Curative resection refers to R0 resection in Japanese Gastric Cancer Treatment Guidelines 2010 (version 3) \[[@B23]\]. Tumor stages were assessed according to the American Joint Committee on Cancer (AJCC) classification system, 7th edition \[[@B24]\]. Additional demographic and clinical data are summarized in [Table 1](#tab1){ref-type="table"}. The study protocol was approved by the ethical committee of the FMUUH.

2.2. Adjuvant Chemotherapy {#sec2.2}
--------------------------

Since there is no established treatment strategy for stage I gastric cancer, decisions to administer AC in those patients were based on their surgeons\' or oncologists\' preference \[[@B25], [@B26]\]. According to the treatment protocol of our institute, stage I GC patients with lymph node metastasis, lymphovascular invasion, or other high risks \[[@B27], [@B28]\] are recommended for AC, unless contraindicated by a patient\'s condition or their refusal. All AC treatments were performed after individually obtaining written informed consent in accordance with the gastric cancer treatment program at the FMUUH that had been approved by its institutional review board. Finally, 144 (13.5%) patients with written informed consent received 5-fluorouracil plus cisplatin AC, at least one cycle \[[@B29]\]. The clinicopathological variables of both groups are summarized in Supplementary [Table 1](#supplementary-material-1){ref-type="supplementary-material"}.

2.3. Systemic Immune Markers {#sec2.3}
----------------------------

Routine clinical laboratory analyses of peripheral blood samples collected within 1 week before the operation were used to ascertain white cell counts, neutrophil counts, and serum albumin. The pretreatment dNLR was calculated as follows: dNLR = neutrophil count to (white cell count-neutrophil count). The cutoff value (2.0) for the pretreatment dNLR was selected as described previously \[[@B20]\]. The cutoff value for the pretreatment hypoalbuminemia (35 g/l) was according to the normal value measured by the used test \[[@B22], [@B30]\]. All the measurements were performed in the central biochemical laboratory at the Department of Clinical Biochemistry and Hematology, FMUUH.

We combined the two risks to establish the SIS defined as follows: patients with both elevated dNLR and hypoalbuminemia (dNLR ≥ 2 and albumin \< 35 g/l, resp.) were assigned score 2, patients with either elevated dNLR or hypoalbuminemia were assigned score 1, and patients with both decreased dNLR and normal albumin (dNLR \< 2 and albumin ≥ 35 g/l, resp.) were assigned score 0.

2.4. Follow-up {#sec2.4}
--------------

All patients were monitored postoperatively by physical examination and laboratory tests, including those for tumor markers (such as CEA and CA 19--9), every 3 months for the first 2 years, every 6 months for the next 3 years, and annually thereafter. In addition, examinations, including chest radiography, abdominopelvic computed tomography (CT), and endoscopy, were performed at least once a year. If necessary, further evaluation, such as positron emission tomography or magnetic resonance imaging, was initiated.

2.5. Statistical Analysis {#sec2.5}
-------------------------

Overall survival (OS) was defined as the time from the day of surgery to the death from any cause. Univariate survival trends were compared using Kaplan-Meier curves and significant differences determined via the log rank test, and those variables that achieved statistical significance in the univariate analysis were entered into the multivariable analysis. Multivariate analysis of prognostic factors was conducted with Cox\'s proportional hazards model. A *p* value \< 0.05 was regarded statistically significant. Statistical analysis was performed using SPSS version 19.0 for Windows (SPSS Inc., Chicago, IL, USA).

3. Results {#sec3}
==========

3.1. Patient Characteristics {#sec3.1}
----------------------------

A total of 1069 patients with pathologically documented stage I GC were included in this study. The study population comprised of 795 (74.4%) males and 274 (25.6%) females. The median age was 60 years (range 18--93). Descriptive clinicopathological and detailed blood count parameters of the study cohort are shown in [Table 1](#tab1){ref-type="table"}. The percentage of patients with dNLR ≥ 2 was 25.4% (272/1069) in contrast to 74.6% (797/1069) for those with dNLR \< 2. Pretreatment hypoalbuminemia (albumin \< 35 g/l) occurred in 174 patients (16.3%). Overall, 925 (86.5%) patients received surgery alone (the non-AC group), and 144 (13.5%) received AC after surgery (the AC group). The baseline characteristics between the groups are shown in [Table 2](#tab2){ref-type="table"}.

3.2. Survival {#sec3.2}
-------------

The 5-year OS rates in T1N0, T1N1, and T2N0 were 95.7%, 85.3%, and 80.0%, respectively (*p* \< 0.001). There were significant differences in 5-year OS between patients with T1N0 and T1N1 (*p* \< 0.001) or T2N0 tumors (*p* \< 0.001). However, no difference was observed in OS between patients with T1N1 tumors and T2N0 tumors (*p* = 0.461) (Supplementary [Figure 1a](#supplementary-material-1){ref-type="supplementary-material"}). The 5-year OS was significantly higher in stage IA patients than in stage IB patients (Supplementary [Figure 1b](#supplementary-material-1){ref-type="supplementary-material"}).

The 5-year OS was significantly worse in high dNLR patients than in low dNLR patients (77.6% versus 94.7%, *p* \< 0.001; [Figure 1(a)](#fig1){ref-type="fig"}). Patients with and without pretreatment hypoalbuminemia also differed significantly in 5-year OS (82.9% versus 92.1%, *p* \< 0.001; [Figure 1(b)](#fig1){ref-type="fig"}).

3.3. Predictive Factors for Survival {#sec3.3}
------------------------------------

The statistically significant prognostic factors identified by univariate analyses are shown in [Table 3](#tab3){ref-type="table"}. Based on the multivariate analysis, the elevated pretreatment dNLR and hypoalbuminemia were independent prognostic factors for OS, together with TNM stage and lymphovascular invasion ([Table 3](#tab3){ref-type="table"}).

3.4. Establishment and Prognostic Impact of the Novel Systemic Immune Score (SIS) {#sec3.4}
---------------------------------------------------------------------------------

Based on the systemic immune prognostic factors identified in the multivariate analysis, we combined the two factors to establish the SIS defined as follows: patients with both high dNLR and the pretreatment hypoalbuminemia were assigned a score of 2, patients with either high dNLR or the pretreatment hypoalbuminemia were assigned a score of 1, and patients with both low dNLR and normal albumin were assigned a score of 0. Namely, patients were given a total score of 0, 1, and 2 based on the sum of the points.

As mentioned above, we generate three subgroups based on the SIS. We found significant differences among the three subgroups. Thus, we combined the three subgroups to establish the SIS classification as follows: the low-risk group has no risk factor (SIS = 0), the medium-risk group has 1 risk factor (SIS = 1), and the high-risk group has two risk factors (SIS = 2) ([Figure 1(c)](#fig1){ref-type="fig"}). The SIS classification also was an independent prognostic factor for OS ([Table 3](#tab3){ref-type="table"}). Supplementary [Figure 2](#supplementary-material-1){ref-type="supplementary-material"} depicts the association between the SIS and TNM as a bubble chart.

3.5. SIS Predicts the Benefits of Adjuvant Chemotherapy {#sec3.5}
-------------------------------------------------------

[Figure 2(a)](#fig2){ref-type="fig"} shows the survival curves for patients with and without AC. In the entire cohort, there was no significant difference in 5-year OS between the groups with and without AC (93·4% versus 90.0%, *p* = 0.109). This lack of a difference was also apparent when the analysis was confined to stage IA (93.7 versus 96.0%, *p* = 0.946) and IB (83.7% versus 79.5%, *p* = 0.426) subgroup patients (Figures [2(b)](#fig2){ref-type="fig"} and [2(c)](#fig2){ref-type="fig"}). Moreover, the survival curves ([Figure 3](#fig3){ref-type="fig"}) show no difference between surgery alone versus surgery + AC according to pretreatment dNLR and hypoalbuminemia.

Surprisingly, for our original SIS system, Kaplan-Meier curves demonstrated that high-risk patients (SIS = 2) with AC had significantly better OS than their counterparts without AC (88.9% versus 69.4%, *p* = 0.023) ([Figure 4(a)](#fig4){ref-type="fig"}), while no significant difference was observed in the low-risk and medium-risk group (94.4% versus 97.6%, *p* = 0.695 and 91.6% versus 81.9%, *p* = 0.130) (Figures [4(b)](#fig4){ref-type="fig"} and [4(c)](#fig4){ref-type="fig"}). In other words, the survival benefit of AC was significant for patients with SIS = 2.

4. Discussion {#sec4}
=============

With the increase in the detection of stage I GC, the number of stage I GC patients who experience recurrence has also increased, which may result in a large health problem in the real world \[[@B2], [@B8]\]. It is thus important to identify patients with apparent early-stage disease who will not be cured by surgery alone and should receive adjuvant chemotherapy (AC). To date, almost all of the data on AC are derived from large-scale clinical trials that included a large proportion of stages II and III patients but no or too few patients with stage I GC \[[@B3]--[@B6]\]. A prospective randomized clinical trial of AC versus surgery alone in stage I GC patients at high risk of recurrence or death is still ongoing (ClinicalTrials.gov identifier NCT01917552). Therefore, it will be clinically useful if a score system can be used to select candidates for AC.

A systemic inflammatory response has been determined to be an important tumor stage-independent predictor of prognosis in various malignances \[[@B31]\]. Pretreatment NLR values are associated with prognosis in various solid tumors, including gastric adenocarcinoma \[[@B15], [@B17], [@B32]\]. In 2012, Proctor et al. \[[@B20]\] reported the dNLR and NLR have similar prognostic value in a large cohort of unselected cancer patients. More recently, Dalpiaz \[[@B33]\] and his colleges found that the pretreatment dNLR was better than NLR in terms of acting as an independent prognostic factor for cancer patients. In this study, we also clearly demonstrate that dNLR was an independent predictor of long-term survival for stage I GC patients (*p* \< 0.001).

In addition to pretreatment NLR, another systemic immune factor was predictive of prognosis in stage I GC in our cohort: pretreatment hypoalbuminemia. There is a growing appreciation that pretreatment hypoalbuminemia can influence the prognosis of cancer patients, possibly through a systemic inflammatory response or impaired immunological response \[[@B34]\]. A recent meta-analysis of 29 studies on variety of gastrointestinal tract solid tumors reported that pretreatment serum albumin levels provide useful prognostic significance in cancer \[[@B30]\]. Several studies have found that low serum albumin level was an independent prognostic factor for worse outcomes in patients with gastric cancer \[[@B35], [@B36]\]. In line with previous studies, the results of the current study show an association between pretreatment hypoalbuminemia and decreased 5-year OS.

As stated above, dNLR and hypoalbuminemia were independent prognostic predictors of survival in patients with stage I GC. Consequently, we created a novel prognostic score named the SIS based on the combination of dNLR and hypoalbuminemia, and we hypothesize that the SIS may provide further information in addition to that from classical pathological prognostic factors for identifying patients who are at high risk for poor prognosis. By grouping the patients on the basis of SIS, we identified three risk groups with distinct survival outcomes, that is, a high-risk group (SIS = 2) with a 5-year OS rate of 71.2%, a medium-risk group (SIS = 1) with a 5-year OS rate of 83.1%, and a low-risk group (SIS = 0) with a 5-year OS rate of 96.1%. When the SIS is used for risk stratification, stage I GC patients could be categorized into three different risk groups displaying a 5-year OS rate difference of almost 25 percentage points.

Proceeding to the next step, NLR can be used to assist in risk stratification and potentially predicting immunotherapy treatment response of patients with nonmetastatic melanoma \[[@B19]\]. Another study from France found that pretreatment serum albumin level \> 35 g/l was the only independent predictive factor of complete response to chemoradiotherapy (CRT) in esophageal cancer patients \[[@B37]\]. Therefore, we hypothesized that SIS may be used to detect patients who can benefit from AC in stage I GC. For stage I gastric cancer, poorly differentiated or higher-grade cancer, LBVI, PNI, or \<50 years of age are considered high-risk features, and adjuvant therapy is recommended in these high-risk patients \[[@B27]\]. Kunisaki et al. \[[@B38]\] revealed that depth of invasion, lymph node metastasis, and LBVI independently influenced prognosis in stage I gastric cancer, and in their report, patients with stage I GC having lymphovascular invasion and stage II GC had similar survival outcomes; this finding suggests that adjuvant chemotherapy is suitable for stage I patients with moderate to severe lymphovascular invasion. However, none of the previous studies compared the prognosis between patients with AC and those without AC. Notably, distinct from the previous studies, we first directly compared the survival of stage I GC patients with or without AC in terms of differences in inflammation-immune status. The patients with an SIS = 2 could achieve significantly better prognosis if treated with AC and should thus be considered candidates for adjuvant treatment.

There were some limitations of the present study. First, it is a single-center retrospective study. Second, we did not perform external or internal validation of our risk model. However, it might be difficult to construct a dataset including a patient population as large as ours for external validation. Despite the large cohort size in this study, the number of events was considered not insufficient to divide patients into training and validation sets for internal validation, and the number of high-risk patients was relatively small. The prognostic significance of the SIS in GC patients remains to be investigated prospectively in other populations and larger cohorts in the future. Third, we did not compare the prognostic value of other SIS, such as PNI, PLR, NLR, and GPS. Finally, the optimal AC cycle for stage I patients had not yet been established.

5. Conclusions {#sec5}
==============

The present study demonstrated that stage I GC patients with elevated pretreatment dNLR and pretreatment hypoalbuminemia were likely to receive a survival benefit from AC. In view of this, the SIS should be included in routine clinical assessments and might also be considered for risk stratification in future clinical trials of AC in early-stage GC. However, it is still necessary to conduct prospective clinical validation studies to confirm the findings of this study.

This study was supported by the Scientific and Technological Innovation Joint Capital Projects of Fujian Province (2016Y9031) and the Construction Project of Fujian Province Minimally Invasive Medical Center (no. \[2017\]171). The second batch of special support funds for the Fujian Province Innovation and Entrepreneurship Talents (2016B013), Youth Scientific Research Subject of Fujian Provincial Health and Family Planning Commission (no. 2015-1-37), and QIHANG Funds of Fujian Medical University (no. 2016QH025).

Data Availability
=================

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval
================

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Disclosure
==========

The funding source hand no role in the design of this article and will not have any role during its execution or publication.

Conflicts of Interest
=====================

The authors declare no conflict of interest.

Authors\' Contributions
=======================

Jun Lu, Chao-hui Zheng, Chang-ming Huang designed this study. Jun Lu, Long-long Cao, Ping Li, Jian-wei Xie, Jia-bin Wang, and Jian-xian Lin collected the data. Jun Lu, Qi-yue Chen, Mi Lin, and Ru-hong Tu carried out the statistical analysis. Jun Lu and Long-long Cao drafted the manuscript. Chao-hui Zheng and Chang-ming Huang revised the manuscript. All authors read and approved the final manuscript.

Supplementary Materials {#supplementary-material-1}
=======================

###### 

Table 1: characteristics of patients with stage I gastric cancer treated with gastrectomy for two treatment groups.

###### 

Click here for additional data file.

###### 

Figure 1: Kaplan-Meier curves for OS of stage I gastric cancer patients according to tumor stage.

###### 

Click here for additional data file.

###### 

Figure 2: the association between the SIS and TNM, depicted as a bubble chart.

###### 

Click here for additional data file.

![Kaplan-Meier curves for high versus low dNLR (a), with versus without pretreatment hypoalbuminemia (b), and patients according to different SIS (c) in the entire cohort.](GRP2018-3249436.001){#fig1}

![Comparison of OS between the adjuvant chemotherapy group and the surgery-only group. (a) Entire group, (b) IA stage subgroup, and (c) IB stage subgroup.](GRP2018-3249436.002){#fig2}

![Comparison of OS between adjuvant chemotherapy group and surgery-only group. (a) dNLR \< 2 subgroup, (b) dNLR ≥ 2 subgroup, (c) hypoalbuminemia subgroup, and (d) nonhypoalbuminemia subgroup.](GRP2018-3249436.003){#fig3}

![Comparison of OS between adjuvant chemotherapy group and surgery-only group. (a) 0 score subgroup, (b) 1 score subgroup, and (c) 2 score subgroup.](GRP2018-3249436.004){#fig4}

###### 

Demographic and clinical features.

  Characteristics                      Number            \%     Characteristics                Number   \%
  ------------------------------------ ----------------- ------ ------------------------------ -------- ------
  Age, years (median, IQR)             60 (18--93)              ASA class                               
  Sex                                                           1-2                            1020     95.4
   Male                                795               74.4   ≥3                             49       4.6
   Female                              274               25.6   Type of surgery                         
  CEA level                                                     Total gastrectomy              284      26.6
   Normal                              871               81.5   Subtotal gastrectomy           785      73.4
   Above normal                        116               10.9   Type of LN dissection                   
   Unknown                             82                7.7    D1                             11       1.0
  CA 19--9 level                                                D1+                            549      51.3
   Normal                              826               77.3   D2                             509      47.7
   Above normal                        152               14.2   Lymphovascular invasion                 
   Unknown                             91                8.5    No                             945      88.4
  Differentiation                                               Yes                            93       8.6
   Well or moderate                    603               56.4   Unknown                        31       2.9
   Poor                                466               43.6   T stage                                 
  Tumor size, cm                                                T1                             821      76.8
   \<3                                 590               55.2   T2                             248      23.3
   ≥3                                  479               44.8   N stage                                 
  Tumor location                                                N0                             895      83.7
   Lower                               595               55.7   N1                             174      16.3
   Middle                              138               12.9   TNM stage                               
   Upper                               207               19.4   IA                             635      59.4
   Multiple                            129               12.0   IB                             434      40.6
  Haemoglobin, g/l (median, IQR)       135 (53--174)            AC                                      
  Albumin, g/l (median, IQR)           40 (20--52)              No (surgery alone)             925      86.5
  WBC, 10^9^/l (median, IQR)           6.0 (2.7--16.6)          Yes (surgery + AC)             144      13.5
  Neutrophils, 10^9^/l (median, IQR)   3.5 (0.7--14.6)          Pretreatment hypoalbuminemia            
  Platelets, 10^9^/l (median, IQR)     217 (80--523)            No                             895      83.7
  dNLR                                                          Yes                            174      16.3
   \<2                                 797               74.6                                           
   ≥2                                  272               25.4                                           

IQR = interquartile range; AC = adjuvant chemotherapy; dNLR = neutrophil count to (white cell count minus neutrophil count); ASA = American Society of Anesthesiologists. Pretreatment hypoalbuminemia: pretreatment serum albumin \< 35 g/l.

###### 

Patient baseline characteristics (adjuvant chemotherapy with surgery versus surgery alone).

  Characteristics                AC group (*n* = 144)   Non-AC group (*n* = 925)   *p* value
  ------------------------------ ---------------------- -------------------------- -----------
  Age, years (median, IQR)       58 (18--81)            60 (20--93)                0.402
  Sex                                                                              0.474
   Male                          103                    692                        
   Female                        41                     233                        
  CEA level                                                                        0.146
   Normal                        112                    759                        
   Above normal                  21                     95                         
   Unknown                       11                     71                         
  CA 19--9 level                                                                   0.701
   Normal                        111                    715                        
   Above normal                  22                     130                        
   Unknown                       11                     80                         
  Differentiation                                                                  
   Well or moderate              78                     525                        
   Poor                          66                     400                        
  Tumor size, cm                                                                   0.419
   \<3                           84                     506                        
   ≥3                            60                     419                        
  Tumor location                                                                   0.591
   Lower                         76                     519                        
   Middle                        20                     118                        
   Upper                         31                     176                        
   Multiple                      17                     112                        
  Type of surgery                                                                  0.522
   Total gastrectomy             43                     241                        
   Subtotal gastrectomy          101                    684                        
  TNM stage                                                                        \<0.001
   IA                            48                     587                        
   IB                            96                     338                        
  Pretreatment dNLR                                                                0.064
   \<2                           116                    681                        
   ≥2                            28                     244                        
  Pretreatment hypoalbuminemia                                                     0.260
   No                            121                    774                        
   Yes                           23                     151                        

###### 

Univariate and multivariate Cox proportional analysis for survival.

  Parameter                         Categories                               Univariate analysis      Multivariate analysis                           
  --------------------------------- ---------------------------------------- ------------------------ ----------------------- ----------------------- ---------
  Age                               \>65 versus \<65                         1.459 (0.974--2.186)     0.067                                           
  Gender                            Male versus female                       1.408 (0.853--2.327)     0.181                                           
  Tumor location                    Upper versus other                       1.254 (0.779--2.019)     0.351                                           
  Tumor size                        ≥30 mm versus \<30 mm                    1.555 (1.041--2.324)     0.031                   1.302 (0.731--1.816)    0.452
  Lymphovascular invasion           Yes versus no                            2.660 (1.509--4.689)     0.001                   2.314 (1.419--4.417)    0.010
  Tumor differentiation             Undifferentiated versus differentiated   1.392 (0.933--2.077)     0.105                                           
  Extent of lymph node dissection   D1+/D1 versus D2                         1.158 (0.643--1.391)     0.211                                           
  AJCC TNM stage                    IB versus IA                             10.183 (5.765--17.987)   \<0.001                 8.098 (5.201--13.145)   \<0.001
  CEA level                         Above normal versus normal               2.433 (1.440--4.110)     0.001                   1.488 (0.873--2.426)    0.319
  CA 19--9 level                    Above normal versus normal               1.363 (0.789--2.356)     0.267                                           
  Adjuvant chemotherapy             No versus yes                            1.557 (0.784--3.092)     0.206                                           
  dNLR                              ≥2 versus \<2                            4.357 (2.910--6.524)     \<0.001                 2.464 (1.301--4.312)    0.004
  Pretreatment hypoalbuminemia      Yes versus no                            2.181 (1.404--3.387)     0.001                   2.102 (1.254--3.576)    0.028
  SIS classification                2 versus ≤1                              4.955 (3.175--7.733)     \<0.001                 3.023 (1.977--6.501)    0.002

CA: carbohydrate antigen; CEA: carcinoembryonic antigen; CI: confidence interval; HR: hazard ratio.
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